Do we need a reflex tachycardia to stand up?

被引:3
|
作者
Fortrat, JO [1 ]
Lemarie, C
Bellard, E
Victor, J
机构
[1] Fac Med, CNRS, Physiol Lab, UMR 6188, F-49045 Angers, France
[2] CHU Angers, Serv Cardiol, Angers 01, France
来源
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY | 2005年 / 28卷 / 09期
关键词
hemodynamics; pacing; rate modulation; vagal syndromes;
D O I
10.1111/j.1540-8159.2005.00216.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Do We Need a Reflex Tachycardia to Stand Up? Background: Sophisticated atrioventricularpocing models are designed to integrate the pacemaker into cardiovascular autonomic control to react appropriately to the cardiovascular demands. Such an approach might be beneficial for patients with vasovagal responses to counterbalance the upright fall in arterial blood pressure by a pacing rate increase. We hypothesized that this approach would improve the cardiovascular response to standing in comparison with a regular pacing mode. Methods: Two 5-minute tilt tests were performed in a random order in 5 patients with a pacemaker (CLS-INOS2) for sinus node disease and atrio-ventricular block. One tilt test was performed in fixed pacing rate (DDD), the other one was performed in close loop stimulation (CLS), which allowed an upright rate-rise pacing. Heart rate, systolic blood pressure, and cardiac output (modelflow) were recorded on a beat-by-beat basis. Results: Changes of systolic blood pressure and cardiac output in response to upright posture were not significantly different between DDD and CLS modes (2.7 +/- 13.2 vs 10.1 +/- 12.9 mmHg and -0.8 +/- 0.3 vs -1.1 +/- 0.4 L/min, respectively). But upright posture led to a tachycardia of more than 30 bpm in 3 patients in CLS mode and to a fall in systolic blood pressure greater than 20 mmHg in 3 patients in CLS mode and only in one patient in DDD mode. Conclusion: Systolic blood pressure and cardiac output are not improved by the upright tachycardia and upright blood pressure response is actually worsened when an upright rate-rise pacing is used. Thus, it appears that tachycardia alone cannot compensate for an upright fall in blood pressure.
引用
收藏
页码:962 / 967
页数:6
相关论文
共 22 条
  • [1] Atrial fibrillation - where do we stand today?
    Olsson, SB
    JOURNAL OF INTERNAL MEDICINE, 2001, 250 (01) : 19 - 28
  • [2] Heterotopic heart transplantation: where do we stand?
    Flecher, Erwan
    Fouquet, Olivier
    Ruggieri, Vito Giovanni
    Chabanne, Celine
    Lelong, Bernard
    Leguerrier, Alain
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2013, 44 (02) : 201 - 206
  • [3] SCORING SYSTEMS - DO WE NEED A DIFFERENT APPROACH
    CIVETTA, JM
    CRITICAL CARE MEDICINE, 1991, 19 (12) : 1460 - 1461
  • [4] Patient-Specific Surgical Planning, Where Do We Stand? The Example of the Fontan Procedure
    de Zelicourt, Diane A.
    Kurtcuoglu, Vartan
    ANNALS OF BIOMEDICAL ENGINEERING, 2016, 44 (01) : 174 - 186
  • [5] Reflex control of sympathetic activity during simulated ventricular tachycardia in humans
    Smith, ML
    Joglar, JA
    Wasmund, SL
    Carlson, MD
    Welch, PJ
    Hamdan, MH
    Quan, K
    Page, RL
    CIRCULATION, 1999, 100 (06) : 628 - 634
  • [6] WILL THE REAL CULPRIT PLEASE STAND UP
    GREENBURG, AG
    CRITICAL CARE MEDICINE, 1993, 21 (11) : 1631 - 1631
  • [7] Intra-aortic balloon pump (IABP) counterpulsation. Do we still need it and if so when?
    Russ, M.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2015, 110 (06) : 402 - 406
  • [8] Quest for the best candidate - How much imaging do we need before prescribing cardiac resynchronization therapy?
    Breithardt, OA
    Breithardt, G
    CIRCULATION, 2006, 113 (07) : 926 - 928
  • [9] Do we need REBOA as an adjunct to ER thoracotomy in German trauma centres? A secondary data analysis from the TraumaRegister DGU®
    Kulla, M.
    Engelhardt, M.
    Holstraeter, T.
    Bleier, D.
    Lefering, R.
    Elias, K.
    ANASTHESIOLOGIE & INTENSIVMEDIZIN, 2018, 59 : 562 - 573
  • [10] SELECTIVE ADENOSINE-2 AGONIST PRODUCES BOTH DIRECT AND REFLEX TACHYCARDIA IN NORMOTENSIVE RATS
    LAPPE, RW
    SHELDON, JH
    COX, BF
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 19 (03) : 460 - 463